GW Pharmaceuticals plc (NASDAQ:GWPH) has made a 72.78% comeback from a 12-month low price of $90.14. It was seen -4.32% lower, changing the price to $155.74, when the closing bell rang on 4/17/2019. At a recent session, the prices were hovering between $155.34 and $163.18. This company shares are 20.98% off its target price of $188.42 and the current market capitalization stands at $4.66B. The recent change has given its price a -4% deficit over SMA 50 and -14.54% deficit over its 52-week high. The stock witnessed -7.36% declines, 21.09% gains and 8.73% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found GWPH’s volatility during a week at 3.54% and during a month it has been found around 3.47%.

GW Pharmaceuticals plc (GWPH) Top Holders

Institutional investors currently hold around $3.9 billion or 81.9% in GWPH stock. Look at its top three institutional owners: Capital Research Global Investors owns $587.14 million in GW Pharmaceuticals plc, which represents roughly 12.6% of the company’s market cap and approximately 15.07% of the institutional ownership. Similar statistics are true for the second largest owner, Capital World Investors, which owns 2,711,572 shares of the stock are valued at $441.36 million. The third largest holder is Scopia Capital Management Lp, which currently holds $218.96 million worth of this stock and that ownership represents nearly 4.7% of its market capitalization.

GW Pharmaceuticals plc 13F Filings

At the end of December reporting period, 149 institutional holders increased their position in GW Pharmaceuticals plc (NASDAQ:GWPH) by some 5,488,890 shares, 135 decreased positions by 1,973,325 and 53 held positions by 16,473,843. That puts total institutional holdings at 23,936,058 shares, according to SEC filings. The stock grabbed 74 new institutional investments totaling 1,557,051 shares while 67 institutional investors sold out their entire positions totaling 506,666 shares.

GW Pharmaceuticals plc (NASDAQ:GWPH) Insider Trades

Multiple company employees have indulged in significant insider trading. GW Pharmaceuticals plc disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CEO Gover Justin D. has sold 23,400 shares of GW Pharmaceuticals plc (GWPH) in the trading session dated Mar. 15, 2019. These shares are worth $327,834 and were traded at $14.01 each. The SEC filing shows that Secor Alicia performed a sale of 900 shares. The Director disposed these shares by way of transaction on Mar. 13, 2019. The company’s shares were given away at $14.2 per share worth to an income of some $12,780 to the account of Secor Alicia.

Director, MACKEY CATHERINE J, sold 888 common shares of GW Pharmaceuticals plc (GWPH) in the open market. In a transaction dated Mar. 13, 2019, the shares were put up for sale at an average price of $14.39, raking in a sum of $12,778. After this sale, 19,284 common shares of GWPH are directly owned by the insider, with total stake valued at $3,003,290.

In the transaction dated Mar. 04, 2019, a great number of shares sold came courtesy the Executive Chairman; GUY GEOFFREY W DR disposed a total of 1,200,000 shares at an average price of $14.69, amounting to approximately $17,628,000. The insider now directly owns 8,245,446 shares worth $1,284,000,000.

GW Pharmaceuticals plc (GWPH) Analyst Guide

Several analysts have released their opinion on GW Pharmaceuticals plc (NASDAQ:GWPH), with 4 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 8 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.77 average brokerage recommendation [T1].